Jain Rachit sold $14K of SDGR

Jain Rachit (EVP & CFO) sold 875 shares of Schrodinger, Inc. (SDGR) at $15.60 on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jain Rachit
Published Jul 17, 2026, 9:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SDGR
Neutral
high confidence
Mentioned
$SDGR
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SDGRNeutralLow
01

Why it matters

The disclosure provides transparency on insider liquidity actions but does not, by itself, change company fundamentals.

02

Market read

Traders may treat this as sentiment noise rather than a catalyst, given the pre-arranged 10b5-1 structure and modest transaction value.

03

What to watch

The sale size is small and does not include any buy-side activity; without additional context (e.g., option exercises, other filings), signal strength is limited.

Relevance 2/10Novelty 3/10Timing: after-hours filing on 2026-07-17 for a 2026-07-16 sale

Background

The article is an SEC Form 4 insider transaction for Schrodinger, Inc. (SDGR) by its EVP and CFO, Jain Rachit.

Company-level read

Ticker impact

$SDGRNeutralHigh confidence
Context

Schrodinger CFO sold 875 shares on 2026-07-16 under a pre-arranged 10b5-1 plan, disclosing $13,647.38 in proceeds.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the disclosed value is modest relative to typical market-moving thresholds.

Market effects

No clear sector read-through from a single, small 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with periods of weaker outlook, so traders may still monitor for follow-on disclosures.

Key entities

  • Schrodinger, Inc.

    Public company filing an insider transaction Form 4.

  • Jain Rachit

    EVP & CFO who executed an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SDGRMed

Schrödinger (SDGR) Q3 2026 Earnings Call Transcript

Schrödinger (SDGR) reported Q3 2026 earnings, highlighting 17% ACV growth and 19% total revenue increase. Key drivers included broader adoption in pharmaceuticals, new product introductions like Bunsen, and growth in biotech and material science sectors. The company raised full-year guidance for ACV and drug discovery revenue. Financials included $44.7M in ACV, $64.5M in total revenue, and a net loss of $38M. Hosted software licensing grew to 45% of software revenue.

$SDGRMed

Schrodinger Inc (SDGR) (Q3 2026) Earnings Call Highlights: Raised Guidance and Strong

Schrodinger Inc (SDGR) reported Q3 2026 earnings with a widened net loss of $38M, despite revenue growth. The company raised guidance, citing strong ACV and customer confidence in its technology. Revenue growth is impacted by a transition to hosted licensing. Bunsen, a new product, is in early access, and material science adoption lags behind pharma/biotech. Drug discovery revenue is milestone-dependent, with intensifying competition in AI-driven molecular discovery.

$SDGRMed

Schrödinger Reports Third Quarter 2026 Financial Results

Schrodinger, Inc. (SDGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Schrödinger Reports Third Quarter 2026 Financial Results Third Quarter ACV of $45 Million, Representing 17% Growth Increases Full-Year 2026 ACV and Drug Discovery Revenue Guidance New York, November 4, 2026 – Schrödinger, Inc. (Nasdaq: SDGR) today announced financial

$SDGRMed

SDGR Looks 19.2% Undervalued on GF Value™

Schrodinger Inc (NASDAQ: SDGR) launched Tectora, a biotech firm focused on immunology and inflammation, backed by a $55M Series A funding. SDGR's P/S ratio is 7.7x, below its 10.3x historical median, suggesting cautious growth expectations. Its GF Score™ is 72/100, indicating moderate fundamental strength with notable valuation and momentum but weak profitability. Insider activity shows $1.4M in selling over the past year, while institutional sentiment is mixed.